Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: Results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials

The Lancet Diabetes and Endocrinology

Volumn 1, Issue 2, 2013, Pages 123-131

  Zinman, Bernard ^a   DeVries, J Hans ^c   Bode, Bruce ^d   Russell Jones, David ^e   Leiter, Lawrence A ^b   Moses, Alan ^f   Johansen, Thue ^g   Ratner, Robert ^h  

^a MOUNT SINAI HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ATLANTA DIABETES ASSOCIATES   (United States)

^e ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^f NOVO NORDISK INC   (United States)

^g NOVO NORDISK A S   (Denmark)

^h GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; INSULIN DEGLUDEC; INSULIN GLARGINE; METFORMIN; GLARGINE; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CARDIOVASCULAR SYMPTOM; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; EVENING DOSAGE; FEMALE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INJECTION; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SELF MONITORING; TREATMENT OUTCOME; AGED; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIA; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84884502135     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70013-5     Document Type: Article

References (17)

1. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012, 29:2104-2114.
2. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012, 14:859-864.
3. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012, 14:944-950.
4. Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia 2011, 54:S426.
5. Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012, 379:1498-1507. for the NN1250-3582 (BEGIN BB T2D) Trial Investigators.
6. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012, 379:1489-1497. for the BEGIN Basal-Bolus Type 1 Trial Investigators.
7. Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012, 35:2464-2471.
8. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013, 15:175-184.
9. Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011, 377:924-931.
10. Declaration of Helsinki. ethical principles for medical research involving human subjects. J Indian Med Assoc 2009, 107:403-405. World Medical Association.
11. ICH harmonised tripartite guideline: guideline for Good Clinical Practice. J Postgrad Med 2001, 47:199-203. International Conference on Harmonisation (ICH).
12. Lantus: European Public Assessment Report-annex I: summary of product characteristics European Medicines Agency, (accessed Dec 1, 2010). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000284/WC500036082.pdf.
13. Ware JE, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME Users manual for the SF-36v2 health survey 2007, QualityMetric Incorporated, Lincoln, RI. 2nd edn.
14. Guidance for industry-diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. Draft guidance US Food and Drug Administration, (accessed Dec 1, 2010). http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071624.pdf.
15. Blonde L, Merilainen M, Karwe V, Raskin P Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets-the TITRATE study. Diabetes Obes Metab 2009, 11:623-631.
16. Heise T, Pieber TR Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007, 9:648-659.
17. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596.